All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Dr. Jason Westin, MD Anderson Cancer Center, Texas, US about the investigator-initiated, single‐arm, open‐label, phase 2 study (NCT02636322) phase II SMART SMART trial of rituximab, lenalidomide, and ibrutinib alone prior to combination with chemo for patients with newly diagnosed DLBCL.
Dr. Westin emphasized this is the first time this has ever been tried, using these drugs without the confounder of chemotherapy.
The Smart Start trial demonstrates the chemotherapy‐free combination of rituximab 375 mg/m2, ibrutinib 560 mg, and lenalidomide 25mg demonstrated an ORR of 86%, and a CRR of 36% prior to any chemotherapy. For all the patients that went onto triplet and get chemotherapy had a CRR of 96%, with PFS at a year of over 90%. Dr. Westin says even though this is a small trial and is not practice-changing yet, but what it does show is the potential for these targeted agents is large cell lymphoma do exist.
Further studies are planned with other novel agents and with fewer cycles of chemotherapy consolidation for patients achieving a CR with RLI alone.
ICML 2019 | Overview of the phase II SMART START trial
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox